- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02328937
Central Corneal Swelling With Silicone Hydrogel Materials
June 18, 2018 updated by: Johnson & Johnson Vision Care, Inc.
Daily Wear Central Corneal Swelling With Etafilcon A and 2 Silicone Hydrogel Materials
This is a prospective, single site, unmasked, cross-over study with three silicone hydrogel contact lenses comparing central corneal swelling.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44124
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 61 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The participant must be at leat 18 years old or older and no greater than 65 years old. Children younger than18 will likely no be able to come back and forth to the clinic during the typical work week as outlined in the above (due to school schedules) and thus not be able to adhere to the protocol.
- The participant must be a current soft contact lens wearer who routinely wears lenses at least 6-8 hours per day and at least 4 days per week for at least the past 3 months.
- Refraction suitable for spherical soft contact lens powers between -1.00 and -6.00 D the participant must be correctable to 20/30 or better at distance with both eyes with dispensed contact lenses.
- The participant must be free of any active anterior segment disorders that would preclude safe contact lens wear. Active anterior segment disorders and evidence of central microbial keratitis are not allowed. However, evidence of past CLPU will be allowed so long as no more than 3 such scars are detected bilaterally. Evidence of more than 3 CLPU-like scars places excessive risk on the participant for subsequent CIE.
- The participant must be correctable to 20/25 or better in each eye with spectacles. Amblyopia will be excluded.
- Flat and steep corneal curvatures from keratometry readings must be between 39.00 and 48.50 D, respectively. Corneal curvatures outside this range may be indicative of a disease state, and the participants are not expected to comfortably wear the study lenses.
- The participant must own or agree to purchase a pair of spectacles that can be worn when lenses are removed, during the washout periods, or in case of ocular discomfort or emergency.
Exclusion Criteria:
- The participant has worn rigid gas permeable contact lenses within the last 30 days or PMMA lenses within the past 12 months. These lenses can transiently alter the corneal shape and influence the fitting of soft contact lenses or alter endothelial cell morphology.
- The participant has an immunocompromising disease or any other systemic disease that in the investigator's opinion will affect ocular health or increase risk during daily contact lens wear.
- The participant is taking any medication that in the investigator's opinion will affect ocular physiology or study participation.
- The participant has an ocular disease or condition such as aphakia, clinically significant corneal dystrophies, corneal edema, external ocular infection, iritis, or had any anterior segment surgery.
- The participant is taking any ocular medications. If a participant was previous taking any ocular medications, the medications must have been discontinued at least 2 weeks prior to enrollment.
- The participant must have less than or equal to grade 2 on any of the slit lamp observations of: upper tarsal papilla, corneal staining, corneal neovascularization, conjunctival injection, and lid erythema or scales.
- The participant is currently pregnant or lactating. Participant who become pregnant during the study will be discontinued.
- An employee or member of the UHCMC Eye Institute or a family member of any study personnel.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: etafilcon A/lotrafilcon B/comfilcon A
Subjects that were randomized to receive the etafilcon A lens 1st, the lotrafilcon B lens 2nd and the comfilcon A lens 3rd.
|
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Names:
|
|
Active Comparator: etafilcon A/comfilcon A/lotrafilcon B
Subjects that were randomized to receive the etafilcon A lens 1st, the comfilcon A lens 2nd and the lotrafilcon B lens 3rd.
|
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Names:
|
|
Active Comparator: comfilcon A/etafilcon A/lotrafilcon B
Subjects that were randomized to receive the comfilcon A lens 1st, the etafilcon A lens 2nd and the lotrafilcon B lens 3rd.
|
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Names:
|
|
Active Comparator: comfilcon A/lotrafilcon B/etafilcon A
Subjects that were randomized to receive the comfilcon A lens 1st, the lotrafilcon B lens 2nd and the etafilcon A lens 3rd.
|
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Names:
|
|
Active Comparator: lotrafilcon B/etafilcon A/comfilcon A
Subjects that were randomized to receive the lotrafilcon B lens 1st, the etafilcon A lens 2nd and the comfilcon A lens 3rd.
|
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Names:
|
|
Active Comparator: lotrafilcon B/comfilcon A/etafilcon A
Subjects that were randomized to receive the lotrafilcon B lens 1st, the comfilcon A lens 2nd and the etafilcon A lens 3rd.
|
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Central Corneal Swelling
Time Frame: 6-8 Hours Post lens insertion
|
Corneal swelling measurements were taken in the right eye during slit lamp evaluations, 6-8 hours post lens insertion.
The average corneal swelling per lens was reported.
|
6-8 Hours Post lens insertion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Limbal Redness
Time Frame: 6-8 hours post lens insertion
|
Limbal redness was assessed in both eyes using a slit lamp, 6-8 hours post lens insertion.
Redness was assessed in 4 regions of the eye (nasal, temporal, inferior and superior) and was graded with a 5-point scale (i.e.
Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
For each region (nasal, temporal, inferior and superior) the average grade was calculated by lens.
The Total Grade was then calculated by summing all the average grade for each region.
The regional average grade ranges from 0 to 4. The total Grade ranges from 0 to 16.
|
6-8 hours post lens insertion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Actual)
April 1, 2015
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
December 3, 2014
First Submitted That Met QC Criteria
December 29, 2014
First Posted (Estimate)
December 31, 2014
Study Record Updates
Last Update Posted (Actual)
June 19, 2018
Last Update Submitted That Met QC Criteria
June 18, 2018
Last Verified
December 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- CR-5550
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corneal Swelling
-
Johnson & Johnson Vision Care, Inc.CompletedCorneal SwellingCanada
-
Medical University of GrazUnknown
-
Chang Gung Memorial HospitalCompleted
-
Hillel Yaffe Medical CenterUnknownShoulder Arthroscopy | Soft Tissue Swelling
-
University Hospital of FerraraRecruiting
-
Tarek A Abdelsalam, MDCompletedSwelling Lips & FaceEgypt
-
Prof. Dr. med. Andreas HalderRecruitingPostoperative Swelling After TKA | Postoperative Pain After TkaGermany
-
Watim Medical & Dental CollegeCompletedImpacted Mandibular Third Molar Extraction | Post Operative SwellingPakistan
-
Ohio State UniversityCompleted
-
Cairo UniversityNot yet recruitingClinical Evaluation Including Pain and SwellingEgypt
Clinical Trials on etafilcon A
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited Kingdom
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.; Johnson & Johnson K.K. Medical CompanyCompleted
-
Johnson & Johnson Vision Care, Inc.Completed